Co-Chairs
· Weili He, weili.he@abbvie.com
· Min-Hua Jen, m.jen@lilly.com
· Cornelia Dunger-Baldauf, cornelia.dunger-baldauf_ext@novartis.com
Membership in Phase I Effort (June 2023-Oct. 2024)
|
Name
|
Affiliation
|
|
Valentina Bayer
|
BI
|
|
Liang Chen
|
Vertex
|
|
Haitao Chu
|
Pfizer
|
|
Cornelia Dunger-Baldauf2
|
Novartis
Independent consultant from January 1, 2025
|
|
Dai Feng
|
AbbVie
|
|
Jia Guan
|
BI
|
|
Weili He1, 2
|
AbbVie
|
|
Min-Hua Jen1
|
Eli Lilly
|
|
Tae Hyun (Ryan) Jung
|
FDA CDER
|
|
Yingyi Liu
|
AbbVie
|
|
Julia Ma
|
AbbVie
|
|
Shahrul Mt-Isa
|
MSD
|
|
Kate Ren
|
University of Sheffield/NICE EAG
|
|
Min Ren
|
Eisai
|
|
Oumar Sy
|
BMS
|
|
Guido Skipka
|
IQWiG
|
|
Zailong Wang
|
Vertex
|
1 Co-leads of Workstream #1; 2 Co-leads of Workstream #2
Membership in Phase II Effort (Oct. 2024 - Present)
|
Name
|
Affiliation
|
Name
|
Affiliation
|
Name
|
Affiliation
|
|
Weili He (Co-chair)1
|
AbbVie
|
Julia Ma
|
AbbVie
|
Tae (Ryan) Hyun Jung
|
FDA
|
|
Min-Hua Jen (Co-chair)3
|
Eli Lilly
|
Shahrul Mt-Isa1
|
Merck
|
Kate Ren
|
University of Sheffield
|
|
Cornelia Dunger-Baldauf (Co-chair)2
|
Novartis
|
Min Ren
|
Eisai
|
Ian Bridges3
|
Amgen
|
|
Valentina Bayer
|
BI
|
Zailong Wang
|
Vertex
|
Haitao Chu
|
Pfizer
|
|
Dai Feng
|
AbbVie
|
CG Wang
|
Regeneron
|
Jia Quan
|
BI
|
|
Antonio Remiro Azócar2
|
Novo Nordisk
|
Joe Cappelleri
|
Pfizer
|
Zhihong Cai
|
Eli Lilly
|
|
Orlando Doehring
|
GSK
|
Xiang Zhang1
|
CSL Behring
|
Ursula Becker
|
Roche
|
|
Yingyi Liu
|
AbbVie
|
Liang Chen
|
Vertex
|
Paul Cislo2
|
Pfizer
|
1 Co-leads of Workstream #1; 2 Co-leads of Workstream #2; 3 Co-leads of Workstream #3